NTT Electronics expands its 400G Coherent DSP line-up into Data Center Interconnects and longer reach networks
16.9.2022 09:00:00 EEST | Business Wire | Press release
NTT Electronics Corporation, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced addition of a low power consumption 400G Coherent DSP to its product portfolio for enabling multi-rate Ethernet transport and applications far beyond Data Center Interconnects. The new DSP ExaSPEED400-R focuses on 400ZR and OpenZR+ interoperable QSFP-DD applications, and achieves 20% less power consumption than its upper-compatible ExaSPEED400 for CFP2-DCO applications.
The new ExaSPEED400-R supports both OIF 400ZR and OpenZR+ MSA 100G-400G specification at the line side, and provides Ethernet transport with 8x25G-NRZ and 8x50G-PAM4 interfaces at the client side. It supports fully flexible Ethernet formats: 1x100GE, 2x100GE/1x200GE, 3x100GE, and 4x100GE/2x200GE/1x400GE.
“This is a very exciting development enabling the use of a low-power DSP in interoperable coherent QSFP-DD modules for an expansion of the application space by cloud network operations and service providers,” said Atul Srivastava, Co-chair of the OpenZR+ MSA Group.
At ECOC 2022, NTT Electronics will show a video demonstration of QSFP-DD module interoperability at 400G OpenZR+ including over 1000km straight fiber transmission, with the support of its QSFP-DD partners Fujitsu Optical Components Ltd., Molex LLC, and NEC Corporation.
Mogi Masahiro, President, Fujitsu Optical Components America Inc, commented as below. “For many years, from the inception of the coherent optical transmission technology, NTT Electronics and Fujitsu Optical Components (FOC) have established a successful partnership to bring the most advanced optical transceiver products to market. We are now very pleased that interoperable coherent transmission has been achieved successfully between FOC’s QSFP-DD optical transceiver, incorporating NTT Electronics’ new ExaSPEED400-R DSP chip, and multi-vendors’ QSFP-DD transceivers. Using FOC’s optical transceiver which enables transmission distance extension with low-power consumption, we are very pleased to be contributing to the ecosystem of interoperable coherent transceivers for data center and service provider networks.”
“Molex is focused on expanding the reach for data center interconnect beyond 120km, recognizing the industry need for significantly improved performance,” said Joseph Chon, director, Coherent Technology and Product Line Management, Molex Optoelectronics. “Collaborating with NTT Electronics and its module partners has accelerated the overall business opportunity for the interoperable QSFP-DD Interconnect Systems and we look forward to supporting evolving customer requirements in this space.”
“We have been developing and producing the state-of-art digital coherent transceivers for more than a decade.” said Akio Goto, General Manager of Photonic Device Development Department, NEC, “And now, as part of continuous collaborations to expand the digital coherent business with NTT Electronics, we have succeeded in developing QSFP-DD, competitive in the market, by using our technical assets and experience. We are accelerating their deployments for various markets.”
ExaSPEED400-R is now ramping up its production volume.
About NTT Electronics
NTT Electronics has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond systems, ROADM components and FTTH networks. Since 2012 NTT Electronics has been delivering its flag-ship 100G coherent DSP that has been widely adopted in the industry. NTT Electronics is headquartered in Yokohama, Japan with offices in Milan, Italy, San Jose, CA, and Shenzhen, China. For more information, go to http://www.ntt-electronics.com/en/about/overview.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005082/en/
Contact information
NTT Electronics Contacts
Daniele Fadini
Managing Director
NTT Electronics Europe S.r.l
Tel : +39-02-49537430
Email: info@ntt-el-eu.com
Atul Srivastava
Chief Technical Officer
NTT Electronics America, Inc.
Tel: +1-201-566-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom